University of Louisville spinout Talaris has filed for an initial public offering on the Nasdaq Global Market.
Talaris Therapeutics, a US-based cell therapy developer spun out of University of Louisville, has filed for a $100m initial public offering on the Nasdaq Global Market.
The company, which previously operated as Regenerex, has yet to set any terms for the proposed offering.
Founded in 2002, Talaris is developing cell therapies that help prevent the rejection of transplanted organs and eliminate the need for immunosuppression medication for organ transplant patients.
Its lead candidate therapy, FCR001, is…
